The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Desvenlafaxine     4-[2-dimethylamino-1-(1...

Synonyms: Norvenlafaxine, CHEMBL1118, SureCN34864, AGN-PC-00JQID, AG-H-81876, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Norvenlafaxine


High impact information on Norvenlafaxine


Biological context of Norvenlafaxine


Anatomical context of Norvenlafaxine


Associations of Norvenlafaxine with other chemical compounds


Analytical, diagnostic and therapeutic context of Norvenlafaxine


  1. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications. Matoga, M., Pehourcq, F., Titier, K., Dumora, F., Jarry, C. J. Chromatogr. B Biomed. Sci. Appl. (2001) [Pubmed]
  2. The effect of renal disease on the disposition of venlafaxine. Troy, S.M., Schultz, R.W., Parker, V.D., Chiang, S.T., Blum, R.A. Clin. Pharmacol. Ther. (1994) [Pubmed]
  3. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Fogelman, S.M., Schmider, J., Venkatakrishnan, K., von Moltke, L.L., Harmatz, J.S., Shader, R.I., Greenblatt, D.J. Neuropsychopharmacology (1999) [Pubmed]
  4. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. Shams, M.E., Arneth, B., Hiemke, C., Dragicevic, A., Müller, M.J., Kaiser, R., Lackner, K., Härtter, S. Journal of clinical pharmacy and therapeutics. (2006) [Pubmed]
  5. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Lindh, J.D., Annas, A., Meurling, L., Dahl, M.L., AL-Shurbaji, A. Eur. J. Clin. Pharmacol. (2003) [Pubmed]
  6. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Whyte, E.M., Romkes, M., Mulsant, B.H., Kirshne, M.A., Begley, A.E., Reynolds, C.F., Pollock, B.G. International journal of geriatric psychiatry. (2006) [Pubmed]
  7. Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Alfinito, P.D., Huselton, C., Chen, X., Deecher, D.C. Brain Res. (2006) [Pubmed]
  8. Inhibition of P-glycoprotein by newer antidepressants. Weiss, J., Dormann, S.M., Martin-Facklam, M., Kerpen, C.J., Ketabi-Kiyanvash, N., Haefeli, W.E. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  9. A high-performance liquid chromatographic method for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in biological fluids. Hicks, D.R., Wolaniuk, D., Russell, A., Cavanaugh, N., Kraml, M. Therapeutic drug monitoring. (1994) [Pubmed]
  10. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. Klamerus, K.J., Maloney, K., Rudolph, R.L., Sisenwine, S.F., Jusko, W.J., Chiang, S.T. Journal of clinical pharmacology. (1992) [Pubmed]
  11. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Grözinger, M., Dragicevic, A., Hiemke, C., Shams, M., Müller, M.J., Härtter, S. Pharmacopsychiatry (2003) [Pubmed]
  12. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M., Takada, K., Azuma, J. British journal of clinical pharmacology. (1999) [Pubmed]
  13. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Gex-Fabry, M., Rudaz, S., Balant-Gorgia, A.E., Brachet, A., Veuthey, J.L., Balant, L.P., Bertschy, G. Eur. J. Clin. Pharmacol. (2002) [Pubmed]
WikiGenes - Universities